Crossmark

In vivo development of resistance to novel β-lactam/β-lactamase inhibitor combinations in KPC-producing Klebsiella pneumoniae infections: a case series

Crossref DOI link: https://doi.org/10.1007/s10096-024-04958-w

Published Online: 2024-10-10

Published Print: 2024-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Boattini, Matteo

Bianco, Gabriele

Comini, Sara

Costa, Cristina

Gaibani, Paolo
License Information

Text and Data Mining valid from 2024-10-10

Version of Record valid from 2024-10-10
More Information

Article History

Received: 25 July 2024

Accepted: 30 September 2024

First Online: 10 October 2024

Declarations

:

: This study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of A.O.U. Città della Salute e della Scienza di Torino-A.O. Ordine Mauriziano-A.S.L. Città di Torino (protocol code 0048443 on 29 April 2022).

: Informed consent was waived due to the retrospective nature of the study.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below